Better medicine,
fast.

Better medicine,
fast.

Better medicine,
fast.

AI-driven drug formulation redefining therapeutic development.

AI-driven drug formulation redefining therapeutic development.

AI-driven drug formulation redefining therapeutic development.

  • Molecule in. Formulation out.

  • Engineered for pharma.

  • Used by global leaders.

Our mission

Reformulating how the world’s medicines are made.

To make drug development faster, more predictive, and more patient-centered by combining AI, automation, and deep pharmaceutical formulation expertise.

Expertise

The team that helped shape modern drug delivery, now building what comes next.

Expertise

The team that helped shape modern drug delivery, now building what comes next.

AI System

An AI-driven formulation platform, purpose-built for pharma.

AI System

An AI-driven formulation platform, purpose-built for pharma.

Traction

Formulations in the clinic. Partnerships with global pharma.

Traction

Formulations in the clinic. Partnerships with global pharma.

Platform

Molecule in.

Formulation out.

Molecule in.

Formulation out.

01

Molecule

A candidate molecule and target product profile to guide formulation development.

01

Molecule

A candidate molecule and target product profile to guide formulation development.

02

AI-enabled development

AI-guided workflows explore the formulation design space and identify the most promising development path.

02

AI-enabled development

AI-guided workflows explore the formulation design space and identify the most promising development path.

03

Formulation

An optimized, manufacturable formulation ready for the next stage of development.

03

Formulation

An optimized, manufacturable formulation ready for the next stage of development.

Partnerships

In partnership with the companies

bringing medicines to patients.

In partnership with the

medicines to patients.

companies

bringing

Supporting pharma partners from emerging biotechs to leading global pharma companies.

Supporting pharma partners from
emerging biotechs to leading global
pharma companies.

Supporting pharma partners from emerging biotechs to leading global pharma companies.

Supporting pharma partners from emerging biotechs to leading global pharma companies.

News & Research

Science-first. Evidence-driven.

Built for impact.

Science-first. Evidence-

driven.

Built for impact.

Research

Agentic, Data-Grounded Drug Formulation Design

New research from Intrepid Labs demonstrates how agentic AI can identify more TPP-matched formulations within the same experimental budget.

Perspectives

Lab Manager

Riley Hickman, Senior Director of Engineering, explores better ways to measure productivity in AI-driven R&D labs beyond throughput alone.

Company news

Medicine Maker 2026 Power List

Dr. Christine Allen reflects on Intrepid Labs’ latest clinical milestone and how AI could shape the future of drug development.

Research

Agentic, Data-Grounded Drug Formulation Design

New research from Intrepid Labs demonstrates how agentic AI can identify more TPP-matched formulations within the same experimental budget.

Research

Agentic, Data-Grounded Drug Formulation Design

New research from Intrepid Labs demonstrates how agentic AI can identify more TPP-matched formulations within the same experimental budget.

Perspectives

Lab Manager

Riley Hickman, Senior Director of Engineering, explores better metrics for measuring productivity in AI-driven R&D labs.

Perspectives

Lab Manager

Riley Hickman, Senior Director of Engineering, explores better metrics for measuring productivity in AI-driven R&D labs.

Company news

Medicine Maker 2026 Power List

Dr. Christine Allen, CEO and Co-Founder of Intrepid Labs, was named to The Medicine Maker’s 2026 Power List in the Small Molecules category.

Company news

Medicine Maker 2026 Power List

Dr. Christine Allen, CEO and Co-Founder of Intrepid Labs, was named to The Medicine Maker’s 2026 Power List in the Small Molecules category.

Research

Agentic, Data-Grounded Drug Formulation Design

New research from Intrepid Labs demonstrates how agentic AI can identify more TPP-matched formulations within the same experimental budget.

Perspectives

Lab Manager

Riley Hickman, Senior Director of Engineering, explores better ways to measure productivity in AI-driven R&D labs beyond throughput alone.

Company news

Medicine Maker 2026 Power List

Dr. Christine Allen reflects on Intrepid Labs’ latest clinical milestone and how AI could shape the future of drug development.

Research

Agentic, Data-Grounded Drug Formulation Design

New research from Intrepid Labs demonstrates how agentic AI can identify more TPP-matched formulations within the same experimental budget.

Perspectives

Lab Manager

Riley Hickman, Senior Director of Engineering, explores better metrics for measuring productivity in AI-driven R&D labs.

Company news

Medicine Maker 2026 Power List

Dr. Christine Allen, CEO and Co-Founder of Intrepid Labs, was named to The Medicine Maker’s 2026 Power List in the Small Molecules category.

Team

Built by the people who

lead the field.

Prof. Christine Allen

Co-founder & CEO

Dr. Christine Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a professor at the University of Toronto and a fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including president of the Controlled Release Society and editor-in-chief of the Journal of Controlled Release.

Prof. Christine Allen

Co-founder & CEO

Dr. Christine Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a professor at the University of Toronto and a fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including president of the Controlled Release Society and editor-in-chief of the Journal of Controlled Release.

Let’s

talk

Partner with us to bring better medicines to patients, faster.

Let’s

talk

Partner with us to bring better medicines to patients, faster.

Let’s

talk

Partner with us to bring better medicines to patients, faster.

Let’s

talk

Partner with us to bring better medicines to patients, faster.

Ready to

formulate what’s next?

Partner with Intrepid Labs to turn promising molecules into development-ready formulations.

Stay updated

We respect your inbox. Unsubscribe anytime.

AI-powered formulation for modern drug development

© 2026 Intrepid Labs Inc., Toronto, Canada

Ready to

formulate what’s next?

Partner with Intrepid Labs to turn promising molecules into development-ready formulations.

Stay updated

We respect your inbox. Unsubscribe anytime.

AI-powered formulation for modern drug development

© 2026 Intrepid Labs Inc., Toronto, Canada

Ready to

formulate what’s next?

Partner with Intrepid Labs to turn promising molecules into development-ready formulations.

Stay updated

We respect your inbox. Unsubscribe anytime.

AI-powered formulation for modern drug development

© 2026 Intrepid Labs Inc., Toronto, Canada